Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
Authors:
- Stilla BauernfeindSBStilla Bauernfeind
- Sebastian EinhauserSESebastian Einhauser
- Leonid TydykovLTLeonid Tydykov
- Anna-Lena MaderAMAnna-Lena Mader
- Bernd SalzbergerBSBernd Salzberger
- Florian HitzenbichlerFHFlorian Hitzenbichler
- Arno MohrAMArno Mohr
- Ralph BurkhardtRBRalph Burkhardt
- Ralf WagnerRWRalf Wagner
- David PeterhoffDPDavid Peterhoff
Open Access
- 25 September 2022
- Vol. 10 (10) , 1608
Abstract
In a previous study, we described a highly significant association between reactogenicity and SARS-CoV-2 RBD IgG titers and wild-type neutralization capacity in males after basic vaccination with BNT162b2. The objective of this study was to assess whether this benefit was long lasting and also evident after BNT162b2 booster vaccination. Reactogenicity was classified into three groups: no or minor injection site symptoms, moderate (not further classified) and severe adverse reactions (defined as any symptom(s) resulting in sick leave). We initially compared 76 non-immunocompromised individuals who reported either no or minor injection site symptoms or severe adverse reactions after second vaccination. In total, 65 of them took part in another blood sampling and 47 were evaluated after booster vaccination. 26 weeks after second vaccination, men who reported severe adverse reactions after second vaccination had 1.7-fold higher SARS-CoV-2 RBD IgG titers (p = 0.025) and a 2.5-fold better neutralization capacity (p = 0.006) than men with no or only minor injection site symptoms. Again, no association was found in women. Reactogenicity of BNT162b2 booster vaccination was different from second vaccination according to our classification and was no longer associated with SARS-CoV-2 RBD IgG titers or wild-type neutralization capacity. To conclude, after BNT162b2 basic vaccination, the association between reactogenicity and humoral immune response in men persisted over time but was no longer detectable after BNT162b2 booster vaccination.Keywords
This publication has 26 references indexed in Scilit:
- Can reactogenicity predict immunogenicity after COVID-19 vaccination?The Korean Journal of Internal Medicine, 2021
- SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3New England Journal of Medicine, 2021
- Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?PLOS ONE, 2021
- Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective studyThe Lancet Regional Health - Europe, 2021
- Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody ResponseVaccines, 2021
- Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralizationInfection, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- The how’s and what’s of vaccine reactogenicitynpj Vaccines, 2019
- Sex differences in immune responsesNature Reviews Immunology, 2016